Top COVID-19 Deals (Part III): Biopharma and Govt. Institutions

The emergence of the coronavirus SARS-CoV-2 and the COVID-19 pandemic has spurred global healthcare and life sciences companies- as well as government agencies- to partner at unprecedented speed to develop vaccines- treatments- and kits
This article covers the last six months of deal data provided by Chris Dokomajilar of DealForma
During the last six months (up to Jun 25- 2020) around 403 deals were made- the breakup of deals are as follows:

107 were done between biopharma companies-
88 between biopharma and govt. organizations/foundations/consortium
61 between biopharma and universities
60 between biopharma/medical devices/diagnostics/digital health companies
33 among universities and academic institutions

We have compiled a list of 20 deals among biopharma companies and government organizations based on transaction values.

1. Barda Contract Service Deal with AstraZeneca to Develop Azd1222 Recombinant Adenovirus Vaccine (formerly ChAdOx1 nCoV-19)

Date: May 21- 2020

Deal Value: $1.2B

BARDA signed a contract service deal with AstraZeneca to develop and manufacture the AZD1222 recombinant adenovirus vaccine (formerly ChAdOx1 nCoV-19) for COVID-19. AZD1222 was developed by Oxford University's Jenner Institute- working with the Oxford Vaccine Group. AstraZeneca to manufacture 400 million doses and secure total manufacturing capacity for 1 billion doses by September 2020. AstraZeneca to receive $1B from BARDA to support P-III development.

2. Johnson & Johnson Research Partnership with BARDA

Date: Feb 11- 2020

Deal Value: $1B

Johnson & Johnson (J&J) signed a research partnership with the Biomedical Advanced Research and Development Authority (BARDA) to develop a vaccine using Janssen's AdVac and PER.C6 technologies for the treatment of coronavirus disease (COVID-19). Additionally- J&J to upscale the vaccine manufacturing facility. Financials were not disclosed but BARDA to fund the P-I study to accelerate the development of a vaccine candidate. On Mar 30- 2020- J&J selected the lead vaccine candidate for coronavirus disease and expected to initiate the human study by Sep 2020. Johnson & Johnson intends to launch the Vaccine in early 2021 with a global supply of over one billion. BARDA and J&J to co-fund the vaccine development program more than $1B- plus an additional undisclosed commitment from BARDA.

3. BARDA Contract Service Deal with Phlow

Date: May 19- 2020

Deal Value: $0.81B

BARDA signed a contract service deal with Phlow to manufacture up to 1.6M doses of five essential generic medicines used in the prevention of COVID-19- including medicines for sedation- pain management- and certain antibiotics. Phlow to receive $354M upfront with an option payment of $458M from BARDA.

4. Emergent BioSolutions Contract Service Deal with Health & Human Services (HHS)

Date: Jun 01- 2020

Deal Value: $0.68M

Emergent BioSolutions signed a contract service deal with Health & Human Services to manufacture COVID-19 vaccines. Emergent BioSolutions to receive $542.7M. Additionally- HHS to provide $85.5M for the expansion of product fill/finish capacity.

5. BARDA Grant to Moderna for its mRNA-1273 SARS-CoV-2 Vaccine

Date: Apr 16- 2020

Deal Value: $0.48B

Moderna received $483M as a grant from the Biomedical Advanced Research and Development Authority (BARDA) to develop Moderna's mRNA vaccine candidate- mRNA-1273 for SARS-CoV-2.

6. Government of Canada Grant to AbCellera to Discover Antibodies for the Treatment of COVID-19

Date: May 03- 2020

Deal Value: $0.175B

AbCellera received $175.6M as a grant from the Government of Canada to discover antibodies for the prevention of COVID-19 and to build technology and manufacturing infrastructure for antibody therapies.

7. SiO2 Materials Science Contract Service Deal with BARDA

Date: Jun 08- 2020

Deal Value: $0.143B

SiO2 Materials Science signed a contract service deal with the Department of Defense's Joint Program Executive Office for Chemical- Biological- Radiological- and Nuclear Defense (JPEO-CBRND) in partnership with the Biomedical Advanced Research and Development Authority (BARDA) to accelerates the production of SiO2 Materials' primary packaging platform for storing vaccines and therapeutics of SARS-CoV-2. SiO2 to receive $143M for the contract.

8. HHS-DOD Defense Production Act (DPA) Contract Service Deal with ApiJect for Population-scale Emergency Drug Injection Solution

Date: May 12- 2020

Deal Value: $0.138B

The U.S. Department of Health and Human Services and Department of Defense signed a contract service deal with ApiJect under the Defense Production Act (DPA) to accelerate the development of high-speed population-scale emergency drug injection solutions with prefilled syringes through its subsidiary RAPID USA under its emergency program Project Jumpstart. ApiJect to receive $138M for the contract.

9. Novavax Contract Service Deal with the US Department of Defense

Date: Jun 04- 2020

Deal Value: $0.06B

Novavax signed a contract service deal with the US Department of Defense to manufacture the antigen component and Matrix-M adjuvant component of the vaccine- NVX-CoV2373 for 10 million doses of vaccine for the prevention of COVID-19. Novavax to receive $60M from DoD.

10. BARDA Contract Service Deal with Emergent Biosolutions to Develop Plasma-Based Therapeutics for COVID-19

Date: Apr 09- 2020

Deal Value: $0.036B

BARDA signed a contract service deal with Emergent Biosolutions to develop plasma-based therapeutics for COVID-19. Emergent's Center for Innovation in Advanced Development and Manufacturing to conduct the research and to receive $14.5M from BARDA and is eligible to receive up to $22M for additional development.

11. BARDA Contract Service Deal with Genentech to Develop Actemra for COVID-19

Date: Apr 06- 2020

Deal Value: $0.025B

BARDA signed a contract service deal with Genentech to develop Actemra for the treatment of COVID-19. Genentech to receive $25M from BARDA to support the development.

12. BARDA Grant to SAB Biotherapeutics

Date: Apr 02- 2020

Deal Value: $0.016B

SAB Biotherapeutics along with the Department of Defense Joint Program Executive Office for Chemical- Biological- Radiological- and Nuclear Defense (JPEO-CBRND) to receive $7.2M as a grant from BARDA to complete manufacturing and preclinical studies- with an option to conduct a P-I study of SAB-185 for the treatment of COVID-19. On Apr 16- 2020- BARDA expanded the contract- and SAB Biotherapeutics to receive up to $9.4M.

13. BARDA Grant to Emergent to Develop COVID-HIG

Date: Apr 02- 2020

Deal Value: $0.014B

Emergent BioSolutions to receive $14.5M as a grant from BARDA to develop COVID-HIG- a human plasma-derived therapy candidate for the prevention of SARS-CoV-2.

14. DOD Contract Service Deal with Ology Bioservices for COVID-19

Date: Mar 23- 2020

Deal Value: $0.014M

The Department of Defense (DOD) signed a contract service deal with Ology Bioservices for the development and manufacturing of monoclonal antibodies for the prevention of Coronavirus disease- COVID-19. Ology to receive $14M.

15. Ology Bioservices and Inovio Contract Service Deal with Department of Defense

Date: Mar 24- 2020

Deal Value: $0.011B

Ology Bioservices and Inovio signed a contract service deal with the Department of Defense to manufacture Inovio's DNA vaccine (INO-4800) for prevention of COVID-19 virus infection to deliver the vaccine rapidly and efficiently to the Department of Defense. Ology Bioservices to receive $11.9M from the Department of Defense.

16. Government of Quebec Grant to Medicago

Date: Mar 21- 2020

Deal Value: $0.007B

Medicago to receive $7M as a grant from the Government of Quebec to develop a vaccine for the prevention of COVID-19.

17. Horizon 2020 Grant to Cobra Biologics

Date: Mar 30- 2020

Deal Value: $0.003B

Cobra Biologics and Karolinska Institutet to receive $3.3M as a grant from Horizon 2020 to develop phase I clinical trial testing of a DNA vaccine for the prevention of COVID-19.

18. NIH Grant to CytoAgents

Date:May 13 - 2020

Deal Value: $0.001B

CytoAgents to receive a $1.6M Phase-2 SBIR grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) to develop GP1681 for the prevention of Influenza and COVID-19.

19. Israel Innovation Authority (IIA) Grant to Enlivex

Date: Apr 13 - 2020

Deal Value: $0.001B

Enlivex to receive $1.5M as a grant from Israel Innovation Authority (IIA) to develop Allocetra for the prevention of COVID-19 and organ dysfunction associated with sepsis.

20. NIH Grant to Adjuvance

Date: May 19- 2020

Deal Value: $0.001B

Adjuvance to receive $1.47M as a grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to evaluate TQL1055 for the prevention of COVID-19.